These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia. Tian L; Tan Y; Chen D; Lv M; Tan S; Soares JC; Zhang XY Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():259-64. PubMed ID: 24995685 [TBL] [Abstract][Full Text] [Related]
69. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Woo SI; Kim JW; Rha E; Han SH; Hahn KH; Park CS; Sohn JW Psychiatry Clin Neurosci; 2002 Aug; 56(4):469-74. PubMed ID: 12109967 [TBL] [Abstract][Full Text] [Related]
70. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia. Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210 [TBL] [Abstract][Full Text] [Related]
71. A neuroendocrine study of supersensitivity in tardive dyskinesia. Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219 [TBL] [Abstract][Full Text] [Related]
72. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver H; Geraisy N; Schwartz M J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856 [TBL] [Abstract][Full Text] [Related]
73. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620 [TBL] [Abstract][Full Text] [Related]
74. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808 [TBL] [Abstract][Full Text] [Related]
75. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329 [TBL] [Abstract][Full Text] [Related]
76. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. de Montigny C; Chouinard G; Annable L Psychopharmacology (Berl); 1979 Nov; 65(3):219-23. PubMed ID: 117492 [TBL] [Abstract][Full Text] [Related]
77. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Wegner JT; Catalano F; Gibralter J; Kane JM Arch Gen Psychiatry; 1985 Sep; 42(9):860-5. PubMed ID: 2864029 [TBL] [Abstract][Full Text] [Related]
78. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Mukherjee S; Roth SD; Sandyk R; Schnur DB Psychiatry Res; 1989 Jul; 29(1):17-27. PubMed ID: 2772097 [TBL] [Abstract][Full Text] [Related]
79. Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. Hui L; Han M; Yin GZ; Zhang Y; Huang XF; Qian ZK; Gu WG; Gu XC; Zhu XM; Soares JC; Ning Y; Zheng Y; Du XD; Zhang XY Schizophr Res; 2017 Apr; 182():104-109. PubMed ID: 27776953 [TBL] [Abstract][Full Text] [Related]
80. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Smith JM; Oswald WT; Kucharski LT; Waterman LJ Psychopharmacology (Berl); 1978 Jul; 58(2):207-11. PubMed ID: 98792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]